Generic Name and Formulations:
C1 esterase inhibitor (human) 500 Units/vial; lyophilized pwd for IV infusion after reconstitution; preservative-free.
Shire US, Inc.
Indications for CINRYZE:
Routine prophylaxis against angioedema attacks in patients ≥6yrs with hereditary angioedema (HAE).
Give by IV infusion at a rate of 1mL/min (10mins). ≥12yrs: 1000 Units every 3–4 days. May consider doses up to 2500 Units (max 100 Units/kg) every 3–4 days if inadequate response.
<6yrs: not established. Give by IV infusion at a rate of 1mL/min (5mins). 6–11yrs: 500 Units every 3–4 days. May adjust dose up to 1000 Units every 3–4 days based on response.
Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease agent). Have epinephrine available to treat hypersensitivity reactions. Monitor patients with known risk factors for thrombotic events. Pregnancy. Nursing mothers.
Headache, nausea, rash, vomiting, fever; thrombotic events, hypersensitivity reactions (may be severe; discontinue if occur).
To report infections that may have been transmitted by Cinryze, call CinryzeSolutions at (877) 945-1000.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|